TREMFYA® offers 5-year skin
clearance,3 so patientscan get
back to feeling their best.1

Over 50% of TREMFYA® patients achieved and maintained PASI 100 over 5 years3




NRI through Week 48, then TFR beyond Week 48.
PASI = Psoriasis Area and Severity Index; NRI = Non-responder imputation; TFR = Treatment Failure Rules.
Includes patients randomised to TREMFYA® at baseline and to placebo who crossed over to TREMFYA® at week 16.



 
 
 
 
 
REFERENCES SEE MORE OF THE LATEST DATA
ON THE JANSSEN MEDICAL CLOUD™		 PRESCRIBING
INFORMATION
 
 
TREMFYA® is indicated for adults with moderate-to-severe plaque
psoriasis (Pso) who are candidates for systemic therapy.10

Tremfya®, alone or in combination with methotrexate (MTX), is indicated
for the treatment of active psoriatic arthritis in adult patients who have
had an inadequate response or who have been intolerant to a prior
disease-modifying antirheumatic drug (DMARD) therapy. 10

Please ensure you review your local Prescribing Information and/or
Summary of Product Characteristics and directly consult
your local Janssen affiliate to address questions.		 Privacy notice  Legal notice

This is published by Janssen Pharmaceutica NV which is solely responsible
for its content. It is intended for EMEA Healthcare professionals.
Third party trademarks used herein are trademarks of their respective owners.
Date of preparation: March 2021.  CP-214600